Ann: Positive DEP docetaxel Phase 2 results, page-23

The announcement seemed, to me, to be a little bit downbeat. Perhaps the efficacy figures were not as good as was first hoped. Perhaps because breast cancer did not get a mention. Perhaps because the trial has been running for so long and SPL staff are a bit jaded and want to move on to newer stuff.
But these results, like cabazitaxel, are very good (and better than I expected).
The most positive aspect for me is the much greater penetration of DEP Docetaxel into the tumours - x10 to x60, proving again that the DEP platform works very well at targeting drugs.
This is a valuable drug with great commercial potential. Let’s hope 2024 brings us the hoped for deals we have been waiting for for so long.